HATD is the only non-profit that provides funding and technical advice on health to both Palestinian and Israeli communities; and the only one that fosters cooperation between grou
Learn about THROMBATE III (antithrombin III [human]) efficacy, important safety information and approved indication. A treatment option for hATd.
Nov 18, 2025 · With this action, Thrombate III has become the first and only antithrombin concentrate approved for adult and pediatric patients with hereditary antithrombin defici
Nov 18, 2025 · The FDA has approved an expanded indication of Grifols' antithrombin III (human) (THROMBATE III) to include pediatric patients diagnosed with hereditary antithrombi
Nov 21, 2025 · The FDA has expanded the approval of Thrombate III to include pediatric patients with hATd to treat and prevent thromboembolism.
What is HATD’s theory of change and how does it link with past research on PtH and the engagement of other organizations in PtH, particularly as it pertains to the Israeli-Palest
Use these resources to better understand the use of Thrombate III in patients with hATd for management of VTE due to low antithrombin levels.
Dec 7, 2025 · On November 18, 2025, the FDA expanded the indication of antithrombin III (human) (THROMBATE III) to include pediatric patients with hereditary antithrombin deficien
May 2, 2025 · Trip Diary From HATD Executive Director’s Travel To The Middle East May 2, 2025
Learn about AT III deficiency, prevalence in the United States. Information about THROMBATE III (antithrombin III [human]) treatment option for hATd patients.